(RTTNews) - Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's ...
Zacks.com on MSN4h
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
"Latino male Trump voter told CNN mass deportation won't extend to law-abiding workers. 'That wouldn’t be fair. They need to ...
Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...
On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Renaissance Technologies took new stakes in Micron Technology (NASDAQ:MU), Eli Lilly (NYSE:LLY), and Cisco Systems ...
Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...
Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...
With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the ...
Looking for the latest stock opportunities in December 2024? We have you covered. Click to read our top stock picks to ...
On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback